BioMark Diagnostics Inc
F:20B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BioMark Diagnostics Inc
F:20B
|
CA |
|
I
|
Infrastrutture Wireless Italiane SpA
F:WI8
|
IT |
|
Arcticzymes Technologies ASA
F:B4V
|
NO |
Intrinsic Value
The intrinsic value of BioMark Diagnostics Inc (20B) under the Base Case is 0.001 EUR per share. Compared with the current market price of 0.286 EUR, the stock appears Overvalued by 100% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What BioMark Diagnostics Does
BioMark Diagnostics Inc. is a molecular diagnostics company that develops blood- and urine-based tests for cancer detection and monitoring. Its products are meant to help find signs of disease earlier, support diagnosis, and track whether cancer is returning or responding to treatment. The company’s work centers on biomarker testing, where it looks for biological signals linked to specific cancers rather than selling drugs or hospital equipment.
- Headquarters
- Canada CA
- IPO date
- Nov 3, 2014
Revenue & Expenses Breakdown
BioMark Diagnostics Inc
Earnings Waterfall
BioMark Diagnostics Inc
The intrinsic value for BioMark Diagnostics Inc (20B) under the Base Case is 0.001 EUR.
Compared with the current market price of 0.286 EUR, the stock appears Overvalued by 100% .